Skip to content

Levamisole on alternate days compared to steroids made daily during infections to prevent disease relapses in patients with frequently relapsing nephrotic syndrome

Randomized controlled trial to compare the efficacy and safety of converting alternate day to daily prednisolone during infections versus levamisole in children with frequently relapsing and steroid dependent nephrotic syndrome

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/07/006002
Enrollment
138
Registered
2015-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Nephrotic Syndrome

Interventions

Intervention1: Low dose prednisolone on alternate days given daily during infections: Prednisolone given on alternate days at 0.5-0.7 mg/kg, given daily for 7 days during each infection Control Interv

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) Patients with idiopathic steroid responsive nephrotic syndrome with frequent relapses or steroid dependence in the preceding 6 months b) Age at onset of frequent relapses or steroid dependence between 2 and 18 years c) Prednisolone requirement d) Parents willing to give informed written consent

Exclusion criteria

Exclusion criteria: a) Known etiology (e.g., systemic lupus erythematosus, IgA nephropathy, amyloidosis) b) Prior therapy with levamisole, cyclosporine, tacrolimus or azathioprine c) Therapy with oral or intravenous cyclophosphamide or intravenous rituximab in the preceding 6 months d) Thrombocytopenia, leukopenia or deranged liver function tests e) Known chronic infection (tuberculosis, HIV, hepatitis B or C) f) Known malignancy g) Severe malnutrition (WHO classification); body mass index >30 or height h) Presence of cataract or glaucoma i) Estimated glomerular filtration rate j) Residing more than 100 km away or unwilling to come for regular follow-up

Design outcomes

Primary

MeasureTime frame
Proportion of patients with frequent relapsesTimepoint: 1 year

Secondary

MeasureTime frame
Adverse effects associated with therapy (costicosteroids: Cushingoid habitus, obesity, hypertension, glaucoma, cataract; levamisole: leukopenia, thrombocytopenia, rash, seizures)Timepoint: 1 year;Cumulative prednisolone doseTimepoint: 1 year;Frequency and type of infectionsTimepoint: 1 year;Frequency of relapsesTimepoint: 1 year;Growth velocityTimepoint: 1 year;Proportion of patients wiht infection associated relapsesTimepoint: 1 year;Proportion of patients with sustained remissionTimepoint: 1 year;Time to first relapseTimepoint: 1 year

Countries

India

Contacts

Public ContactArvind Bagga

All India Institute of Medical Sciences

arvindbagga@hotmail.com91-11-26593472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026